Skip to main content
OpenTrials
Completed

NCT Number: NCT02776267

Percutaneous Coronary Intervention With the Angiolite Drug-eluting Stent: an Optical Cohenrece Tomography Study

The purpose of this study is to perform a first-in-man assessment of feasibility, exploratory efficacy and clinical performance of the novel Angiolite drug-eluting stent (iVascular, Barcelona, Spain) utilizing intracoronary optical coherence tomography (OCT).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Vall D'Hebron, Barcelona, Spain

Loading trial locations.

About this study

This is a prospective registry including patient scheduled for a clinically-indicated percutaneous coronary intervention (PCI) of a de novo epicardial lesion with indication for drug-eluting stent implantation. Following study enrolment and PCI/stent with the Angiolite DES, patients will be scheduled for follow-up surveillance coronary angiography and OCT with the C7-XRTM Fourier Domain OCT system with C7 DragonflyTM catheter (St Jude Medical, Minneapolis, MN) or with the Terumo LunawayTM OCT system with fastview catheter (Terumo Medical Corporation, Tokyo, Japan). An adaptive design component of the study will randomize patients to either 3-month or 6-month angio/OCT follow-up. Clinical follow-up will occur at 30 days, 3 months, 6 months, 12 months and 24 months post PCI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients scheduled for clinically-indicated PCI of a de nove epicardial lesion, including those with chronic stable angina, ACS (defined as NSTEMI or ACS with negative cardiac enzymes) or in the setting of elective PCI.
  • Indication for DES implantation
  • Target lesion must have visually estimated stenosis ≥50% and one of the following: stenosis ≥70% or evidence of ischemia
  • Strong preference for single stent coverage per lesion, but if unexpected clinically indicated second stent placement with overlap is needed, these patients will not be excluded from optical coherence tomographic follow-up
  • Target lesion, if possible, should be predilated/pretreated

Exclusion criteria

  • Age >85 years
  • Acute ST segment elevation MI (STEMI)
  • Cardiogenic shock
  • Known left ventricular ejection fraction <30%
  • Contraindication for dual antiplatelet therapy (DAPT) for at least 6-month duration
  • Iodinated contrast allergy
  • Renal impairment with serum creatinine >2.0 mg/dL
  • Anticipated medical non-compliance
  • Life-expectancy <12 months
  • Chronic total occlusion (CTO) in the target vessel
  • Bifurcation lesion requiring a two-stent strategy
  • In-stent restenosis
  • Severe lesion/segment angulation/tortuosity
  • Severe vessel/lesion calcification
  • Simultaneous PCI within the same or different vessel during the same procedure
  • Lesion unsuitable for OCT (proximal lesions <10 mm from ostium of left main or right coronary arteries)
  • Lesion length >18 mm
  • Stent length >24 mm
  • Stent diameter ≤2.5 mm and > 4.0 mm
  • Unprotected left main coronary artery disease (≥50% diameter stenosis)
  • >1 lesion
  • Planned use of 2 overlapping stents

Treatment and study plan

Angiolite stent

Device

Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.

Other names: (Angiolite CE Mark reference number: 2014 12 0833 ED)

Primary outcomes

  1. Neo-intimal coverage

    Time frame: 6-month

    Strut-based analysis: % of covered struts. Cross-sectional analysis: number of cross-sections with RUTTS (Rate of uncovered to total number of struts) score>30%.

    Measured by an independant OCT laboratory

  2. Neo-intimal obstruction

    Time frame: 6-month

    Strut-based analysis: mean neointimal thickness (µm). Cross-sectional analysis: neointimal volume obstruction (%). Measured by an independant OCT laboratory

Secondary outcomes

  1. Neo-intimal coverage

    Time frame: 3-month

    Strut-based analysis: % of covered struts. Cross-sectional analysis: number of cross-sections with RUTTS (Rate of uncovered to total number of struts) score>30%.

    Measured by an independant OCT laboratory.

  2. Neo-intimal obstruction

    Time frame: 3-month

    Strut-based analysis: mean neointimal thickness (µm). Cross-sectional analysis: neointimal volume obstruction (%). Measured by an independant OCT laboratory.

  3. Apposition

    Time frame: 3- and 6-month

    Strut-based analysis: incomplete strut apposition (ISA) rate. Cross-sectional analysis: % frames with ISA. Measured by an independant OCT laboratory.

  4. In-stent angiographic late lumen in mm

    Time frame: 6-month

    Confirmed by Imaging and measured by an independant QCA laboratory

  5. In-stent and in-segment restenosis

    Time frame: 6-month

    Confirmed by Imaging and measured by an independant QCA laboratory (Reduction in percent diameter stenosis of stented segment of >= 50%

  6. CV death

    Time frame: 6-month and 1-year

    Death from any known cardiovascular etiology

  7. Myocardial infarction

    Time frame: Peri-procedural, spontaneous

    Peri-procedural myocardial infarction will be defined according to the 3rd universal definition of MI Following PCI, myocardial infarction will be defined according to the specific clinical situation of the patient.

  8. Target-lesion revascularization

    Time frame: 24 months

    Any repeat revascularization du to a restenosis within the DES-treated segment

  9. Binary restenosis

    Time frame: 24 months

    Reduction in percent diameter stenosis of stented segment of < vs.>= 50%

Sponsors and collaborators

Lead sponsor

Josep Rodes-Cabau

Other

Collaborators

  • iVascular

Registry information

Official study title

Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study

Important dates

Study start
2015
Primary completion
2017
Study completion
2018
First posted
May 18, 2016
Registry last updated
Jul 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.